ORG Partners’s Inovio Pharmaceuticals INO Stock Holding History

ORG Partners’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8	Closed	-$68	–	1269
2024 Q2	$68	Buy	+8	New	+$84	﹤0.01%	1761
2024 Q1	–	Sell	-8	Closed	-$51	–	784
2023 Q4	$51	Buy	+8	New	+$39	﹤0.01%	1097

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ORG Partners's INO Position: Q3 2024 in Review

ORG Partners sold out of Inovio Pharmaceuticals (INO) in Q3 2024, closing a stake of 8 shares — an estimated $68 sold.

ORG Partners first reported a position in INO in Q4 2023 and held it in 2 quarters. The position peaked at $68 in Q2 2024. 98 funds tracked by Wall St. Rank hold INO as of Q3 2024.

ORG Partners reported no remaining Inovio Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
ORG Partners sold 8 Inovio Pharmaceuticals shares in Q3 2024, an estimated $68.
ORG Partners first reported a position in Inovio Pharmaceuticals in Q4 2023 and held it in 2 quarters.
ORG Partners's Inovio Pharmaceuticals position peaked at $68 in Q2 2024.
98 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.